Chinese pharmaceutical company Chia Tai Tianqing, a subsidiary of Sino Biopharm, announced on Thursday that China's National Medical Products Administration has approved the use of its innovative injection in hemophilia A patients aged 12 and above.

 

The company said that the domestic therapy, a type of recombinant human coagulation factor for injection, is expected to provide high-quality and cost-effective prevention and treatment for approximately 140,000 hemophilia patients in the country.

 

Hemophilia is a hereditary, lifelong disease caused by a lack of coagulation factors, leading to coagulation dysfunction. The main symptoms are spontaneous bleeding or continuous bleeding after mild trauma. The National Health Commission included hemophilia in the first batch of rare diseases list in 2018.

 

However, the treatment needs of hemophilia patients in China are still far from being met because of the shortage in materials to produce the therapies. As such, many patients depend mainly on replacement therapies instead.

 

The company said that its therapy was created based on a newly developed production technique. It ensures high production efficiency and stable processes.

 

Eric Tse, executive director and CEO of Sino Biopharm and president of Chia Tai Tianqing, said that the medicine is expected to further improve the accessibility of medication for hemophilia patients and improve their quality of life.

来源：ChinaDaily

原文链接：https://enapp.chinadaily.com.cn/a/202309/01/AP64f19557a310f3b0aff66757.html